Mainz Biomed N.V., a molecular genetics diagnostic company, has announced a collaborative agreement with Thermo Fisher Scientific to accelerate the development and commercialization of its next-generation colorectal cancer (CRC) screening product.
 
The partnership will leverage Thermo Fisher’s advanced technologies and expertise to enhance Mainz Biomed’s mRNA-based CRC screening test. This non-invasive test, which has shown promising results in clinical trials, aims to detect both early-stage CRC and precancerous lesions.
 
By combining Mainz Biomed’s innovative approach with Thermo Fisher’s technical capabilities, the two companies aim to deliver a highly effective home-collection screening tool to patients worldwide. This collaboration underscores the growing importance of early cancer detection and the potential of advanced molecular diagnostic technologies.
 
Guido Baechler, CEO of Mainz Biomed, said: “This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas. Our product development will be greatly enhanced by Thermo Fisher’s knowledge and scalable, class-leading technologies, providing both partners with a means to accelerate the availability of an innovative new test for colorectal cancer screening around the world.”
 
Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, added: “We are excited at the prospect of working with Mainz Biomed on their next generation screening test and are confident that together we will be able to achieve rapid progress and deliver innovative new assays for the global clinical marketplace.”